Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) gets downgraded to Equal Weight by Morgan Stanley

Analyst Ratings For Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

Story continues below

Today, Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) stock was downgraded by Morgan Stanley from Overweight to Equal Weight.

There are 7 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) is Buy with a consensus target price of $57.3750 per share, a potential 14.16% upside.

Some recent analyst ratings include

  • 4/9/2019-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) gets downgraded to Equal Weight by Morgan Stanley
  • 3/19/2019-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Hold rating reiterated by Barclays with a $52.00 price target
  • 3/19/2019-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Buy rating reiterated by Oppenheimer
  • 3/4/2019-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Buy ➝ Buy rating reiterated by Needham & Company LLC with a $56.00 price target
  • 11/15/2018-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Outperform rating reiterated by William Blair
  • On 3/26/2019 Declan Doogan, Director, sold 11,175 with an average share price of $53.69 per share and the total transaction amounting to $599,985.75.
  • On 3/22/2019 Declan Doogan, Director, sold 5,351 with an average share price of $53.66 per share and the total transaction amounting to $287,134.66.
  • On 3/14/2019 Vlad Coric, CEO, sold 100,000 with an average share price of $50.09 per share and the total transaction amounting to $5,009,000.00.
  • On 3/12/2019 John Tilton, Insider, sold 10,000 with an average share price of $50.11 per share and the total transaction amounting to $501,100.00.
  • On 3/12/2019 Vlad Coric, CEO, sold 51,962 with an average share price of $50.15 per share and the total transaction amounting to $2,605,894.30.
  • On 3/1/2019 Declan Doogan, Director, sold 50,595 with an average share price of $47.17 per share and the total transaction amounting to $2,386,566.15.
  • On 2/27/2019 Declan Doogan, Director, sold 27,045 with an average share price of $45.02 per share and the total transaction amounting to $1,217,565.90.

About Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.

Recent Trading Activity for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
Shares of Biohaven Pharmaceutical Holding Co Ltd closed the previous trading session at 50,26 +0,070 0,14 % with 50.19 shares trading hands.

An ad to help with our costs